Search global stocks & ETFs...Ctrl K

Learn Mode

BMRN - BioMarin Pharmaceutical Inc

34

$51.81

-$1.43 (-2.686%)

At market close

$52.01

$0.20 (0.386%)

After Hours 5/15/26, 11:03 PM

Score

3.37/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

BMRN

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$10.01B

Industry

Biotechnology

EPS (TTM)

$1.37

P/E (TTM)

37.26

Div & Yield

FCF Payout Ratio

P/S (TTM)

3.09

P/B

1.61

Diluted Shares

197.67M

Ex-Dividend

Next Earnings

08-03

Forward P/E

11.25

Payout Ratio

P/FCF (TTM)

13.19

FCF Yield

7.58%

Earnings Yield

2.68%

52 Week Range

Score Card

Explore Scores Tab

3.37

Average

BioMarin Pharmaceutical Inc has grown revenue at 9.9% over the past year, which suggests sales are increasing. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

5.00

Very Good

Management

2.00

Bad

Growth

3.00

Average

Profitability

2.00

Bad

Fin. Health

1.00

Very Bad

Dividends

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-11 17:01:13

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-07 13:17:32

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-05 13:59:42

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-04 16:07:23

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-29 17:07:42

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-27 08:45:12

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-23 16:20:56

Form ARS

Unknown Form Type

Filed on 2026-04-21 16:22:50

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-21 16:21:05

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-21 16:19:01

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 16:09:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-19 16:53:12

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$126.00

143.2%

Avg:

$91.69

77.0%

Low:

$55.55

7.2%

(% change is relative to the current stock price: $51.81)

Analyst Recommendations

Go to Analyst Tab

4.13

Good

31%

Strong Buy (10)

50%

Buy (16)

19%

Hold (6)

Sell (0)

Strong Sell (0)

About

Website
https://www.biomarin.com/
Address
770 Lindaro Street, San Rafael California CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1048477

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.

IPO Date

1999-07-23

Industry

Biotechnology

Total Employees

3,221

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

BMRN - BioMarin Pharmaceutical Inc

34

$51.81

-$1.43 (-2.686%)

$52.01

$0.20 (0.386%)

3.37/5

Stock Unlock

Stock Profile

Score Card

Average

Insider Transactions

Market News

Form 4

Filed on 2026-05-11 17:01:13

Form 144

Filed on 2026-05-07 13:17:32

Form 10-Q

Filed on 2026-05-05 13:59:42

Form 8-K

Filed on 2026-05-04 16:07:23

Form SCHEDULE 13G

Filed on 2026-04-29 17:07:42

Form 8-K

Filed on 2026-04-27 08:45:12

Form 8-K

Filed on 2026-04-23 16:20:56

Form ARS

Filed on 2026-04-21 16:22:50

Form DEFA14A

Filed on 2026-04-21 16:21:05

Form DEF 14A

Filed on 2026-04-21 16:19:01

Form SCHEDULE 13G/A

Filed on 2026-03-26 16:09:48

Form 4

Filed on 2026-03-19 16:53:12

Financials

Price Targets

143.2%

77.0%

7.2%

Analyst Recommendations

About

Similar Stocks